Acute myeloid leukemiaNews & Research
15 curated articles for Acute myeloid leukemia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- The Journal of biological chemistry Apr 18, 2026
Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.
Mesothelin (MSLN) is a glycosylphosphatidylinositol-anchored cell surface protein that is overexpressed in several solid tumors and in one-third of pediatric acute myeloid leukemia (AML) cases. It represents a validated immunotherapeutic target owing to its lack of expression in normal bone marrow. ...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Annals of hematology Apr 17, 2026
CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.
AML is an aggressive haematological malignancy characterised by uncontrolled proliferation and differentiation arrest of myeloid progenitor/stem cells. Conventional treatment methods principally entail chemotherapy and haematopoietic stem cell transplantation; however, the efficacy of these treatmen...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Leukemia research Apr 16, 2026
The emerging role of plasmacytoid dendritic cell proliferation in acute myeloid leukemia.
The mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm represents a clonal proliferation of plasmacytoid dendritic cells within myeloproliferative and myelodysplastic disorders. This entity was recently recognized as a distinct condition in the fifth edition of the Wor...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Journal of the National Cancer Institute Apr 9, 2026
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children's Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to th...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Molecular therapy : the journal of the American Society of Gene Therapy Apr 2, 2026
CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.
Therapies leveraging chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) are limited by the scarcity of leukemia stem cell (LSC)-specific antigens. Here, we found that CD96 is expressed in 48.3% of AML patients, with higher expression on LSCs than blasts, and is absent on normal...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Genes Mar 28, 2026
The Exosome Landscape in Acute Myeloid Leukemia: From Molecular Mechanisms to Translational Frontiers.
Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy arising from the oncogenic transformation of hematopoietic stem and progenitor cells, resulting in clonal expansion and progressive subclonal diversification. Although considerable advances have deepened our understa...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Nature biotechnology Mar 18, 2026
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein.
Immunotherapies for acute myeloid leukemia (AML) and other cancers are limited by a lack of tumor-specific targets. Here we discover that RNA-binding proteins and glycosylated RNAs (glycoRNAs) form precisely organized nanodomains on cancer cell surfaces. We characterize nucleophosmin (NPM1) as an ab...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Current opinion in pharmacology Mar 16, 2026
Advancements in targeted therapies for acute myeloid leukemia.
For decades, the only therapeutic option for acute myeloid leukemia (AML) had been intensive combination chemotherapy. In recent years, understanding of the molecular mechanisms underlying myeloid oncogenesis has grown immensely and has led to the development of multiple effective small molecule inh...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Blood Mar 12, 2026
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.
Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key end point in clinical trials. The 2025 update of the MRD guideline provides a comprehensive and refined framework for...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Blood Mar 7, 2026
Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia.
Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (mitofusion). In this study, we demonstrate that microRNA-126 (miR-126) maintains LSC function by promoting B-cell lymphoma 2 (BCL-...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Leukemia & lymphoma Mar 7, 2026
Improved overall survival in acute myeloid leukemia over the last 15 years.
This study evaluated changes in overall survival (OS) among patients diagnosed with AML from 2004 to 2019 using the National Cancer Database. The analysis included 67,895 patients aged ≥ 18 years, divided into three diagnosis eras: 2004-2010, 2011-2016, and 2017-2019. Median OS steadil...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Cancers Feb 27, 2026
Management of Acute Myeloid Leukemia: A Review.
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with historically poor outcomes, particularly among older adults and patients harboring high-risk molecular features. Advances in genomic profiling have enabled the development of targeted therapies, reshaping treatment algorithm...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Leukemia Feb 5, 2026
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
SCHEMATIC VIEW OF THE DEVELOPMENT OF CK-AML DRIVEN BY THE TP53 ABSENCE.: The occurrence of the first, often dominant negative TP53 mutation is quickly followed by the loss of the second TP53 allele and numerous further chromosomal aberrations.
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Leukemia Feb 5, 2026
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.
CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapy approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on JAK2 compared...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
- Blood Jan 29, 2026
The proteostasis network is a therapeutic target in acute myeloid leukemia.
Oncogenic growth places great strain and dependence on protein homeostasis (proteostasis). This has made proteostasis pathways attractive therapeutic targets in cancer, but efforts to drug these pathways have yielded disappointing clinical outcomes. One exception is proteasome inhibitors, which are ...
Why it matters: Recent peer-reviewed research on Acute myeloid leukemia that may be relevant for patients and caregivers.
More on Acute myeloid leukemia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.